Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Corvus Pharmaceuticals Q2 EPS $(0.28) Up From $(0.36) YoY

Corvus Pharmaceuticals (NASDAQ:CRVS) reported quarterly losses of $(0.28) per share. This is a 22.22 percent increase over losses of $(0.36) per share from the same period last year.

byBenzinga Newsdesk

August 2, 2021

1 minute read

Corvus Pharmaceuticals (NASDAQ:CRVS) reported quarterly losses of $(0.28) per share. This is a 22.22 percent increase over losses of $(0.36) per share from the same period last year.

Xponential Fitness Q2 EPS $(0.33), Sales $35.80M

By Bill Haddad

August 24, 4:08 PM

Xponential Fitness (NYSE:XPOF) reported quarterly losses of $(0.33) per share. The company reported $35.80 million in sales this quarter.

XPOF

75 Biggest Movers From Friday

By Lisa Levin

July 26, 5:14 AM

Gainers The New Home Company Inc. (NYSE: NWHM) jumped 82.9% to settle at $8.89 on Friday after the company agreed to be acquired by funds managed by affiliates of Apollo Global Management for $9 per share in all-cash transaction.

AACG

Mizuho Maintains Buy on Coherus BioSciences, Lowers Price Target to $25

By Benzinga Newsdesk

May 20, 9:25 AM

Mizuho analyst Salim Syed maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and lowers the price target from $30 to $25.

CHRS

Earnings

Looking into Booking Holdings’s Return on Capital Employed

By Benzinga Insights

August 20, 1:52 PM

After pulling data from Benzinga Pro it seems like during Q2, Booking Holdings's (NASDAQ:BKNG) reported sales totaled $2.16 billion. Despite a 81.99% in earnings, the company posted a loss of $56.00 million.

BKNG

Corvus Pharmaceuticals Q2 EPS $(0.28) Up From $(0.36) YoY

Related Posts

Xponential Fitness Q2 EPS $(0.33), Sales $35.80M

75 Biggest Movers From Friday

Mizuho Maintains Buy on Coherus BioSciences, Lowers Price Target to $25

Looking into Booking Holdings’s Return on Capital Employed